We are testing a new T cell treatment for patients with relapsed or refractory hematologic malignancies. The goal is to see if it can improve outcomes for those who have not responded to other therapies.
Health conditions and diseases that the clinical trial is designed to study and treat.
Relapsed/refractory blood cancers include various types of hematological malignancies such as Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL). These conditions occur when cancer returns after treatment or does not respond to initial therapies.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.